Search

Meet BioClonal, our new member. We talked to its with Paula Garfella Founder & CEO and Jessika Valero, CRO.

ZETA is committed to making a positive contribution by delivering innovative and sustainable strategies that help our customers achieve their Net Zero goals.

GENESIS Biomed inaugurated its new site at Valencia last week at the BioHub VLC, as part of the GENESIS Biomed Annual Conference in the Valencian Community.

The purpose behind our request for the creation of the High Commissioner is to strengthen Spain's commitment to deep technologies at a critical moment for Europe's strategic autonomy.

Funding provided by Nice & Green SA, a Swiss private investor.

In recent years, Biologics and Advanced Therapies (ATs) have emerged as the primary drivers of innovation within the pharmaceutical industry.

The map reveals that 43 AseBio partners are taking direct actions aimed at combating antibiotic resistance through various capabilities. Most of these biotech organizations focus on human health, but

BCN HEALTH has participated in the EASL and AASLD congresses with several communications that have reported on the clinical and economic burden of patients with HDV coinfection and HBV monoinfection

The consultancy firm GENESIS Biomed, a national reference in advisory services for early-stage projects in the biomedical sector, will close 2023 with a turnover of €2M, 25% more than in 2022, due to

Meet UNGRIA Patentes y Marcas, our new ally. We talked with Sergio Escorza Treviño, director del Departamento de Patentes.

It is a recognition of the company, its professionals and the advances achieved in its secretome-based therapies

The satisfaction survey highlights significant findings, such as the positive assessment of the BIOSPAIN 2023 program by over 90% of attendees and the fact that the event has allowed 88% of

Spain needs a clear regulatory framework and support for the biotechnological industry with long-term investments, support that specifically addresses the needs of biotech companies, and measures to

The ENVI Committee of the European Parliament advocates expanding the category 1 of NGTs, allowing their use in organic agriculture, and reducing labeling and traceability obligations.

Lead candidate KYN-5356, a first-in-class small Molecule KAT-II inhibitor advancing toward the clinic for cognitive impairment associated with schizophrenia.

Multiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement.

Oryzon’s CEO, Dr. Carlos Buesa, will attend the LSX Investival Showcase, to be held on November 13 at at Old Billingsgate in London (UK). Click on link for more info about the LSX Investival Showcase